The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company may pursue an initial business combination opportunity in any industry or geographical location.
Company profile
Ticker
ENGN, FRBNU, FRBNW, FRBN
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Latest filings (excl ownership)
15-12G
Securities registration termination
13 Nov 23
8-K
Entry into a Material Definitive Agreement
1 Nov 23
25-NSE
Exchange delisting
31 Oct 23
10-Q
2023 Q3
Quarterly report
27 Oct 23
425
Business combination disclosure
24 Oct 23
8-K
Submission of Matters to a Vote of Security Holders
24 Oct 23
DEFA14A
Additional proxy soliciting materials
17 Oct 23
DEFM14A
Proxy related to merger
29 Sep 23
425
Business combination disclosure
15 Sep 23
8-K
Regulation FD Disclosure
15 Sep 23
Latest ownership filings
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G
CALAMOS INVESTMENT TRUST/IL
14 Feb 24
SC 13G/A
Saba Capital Management, L.P.
8 Feb 24
SC 13G/A
HIGHBRIDGE CAPITAL MANAGEMENT LLC
19 Jan 24
SC 13G/A
Feis Lawrence
1 Nov 23
4
Change in insider ownership
31 Oct 23
4
Change in insider ownership
31 Oct 23
3/A
Initial statement of insider ownership (amended)
31 Oct 23
SC 13G
Sculptor Capital LP
10 Oct 23
SC 13G
Feis Lawrence
6 Oct 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 85.66 k | 85.66 k | 85.66 k | 85.66 k | 85.66 k | |
Cash burn (monthly) | 61.16 k | 30.94 k | 857.92 k | 759.67 k | 24.14 k | |
Cash used (since last report) | 447.67 k | 226.51 k | 6.28 mm | 5.56 mm | 176.72 k | |
Cash remaining | -362.01 k | -140.85 k | -6.19 mm | -5.47 mm | -91.06 k | |
Runway (months of cash) | -5.9 | -4.6 | -7.2 | -7.2 | -3.8 |
Institutional ownership, Q3 2023
72.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 33 |
Opened positions | 1 |
Closed positions | 11 |
Increased positions | 9 |
Reduced positions | 16 |
13F shares | Current |
---|---|
Total value | 96.58 bn |
Total shares | 9.20 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Saba Capital Management | 786.55 k | $8.62 bn |
Calamos Advisors | 750.00 k | $8.24 bn |
Cowen And | 739.32 k | $8.10 bn |
Periscope Capital | 679.08 k | $7.44 bn |
Fir Tree Capital Management | 558.69 k | $6.16 bn |
Westchester Capital Management | 511.27 k | $5.60 bn |
CNH Partners | 459.27 k | $5.03 bn |
Kim | 384.93 k | $4.22 bn |
TENOR CAPITAL MANAGEMENT | 350.00 k | $3.84 bn |
D. E. Shaw & Co. | 320.69 k | $3.54 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Oct 23 | Growth Sponsor FEAC I B.V. Forbion | Class A Ordinary Shares | Sale back to company | Dispose D | Yes | No | 0 | 2,000,000 | 0.00 | 0 |
30 Oct 23 | Growth Sponsor FEAC I B.V. Forbion | Class A Ordinary Shares | Sale back to company | Dispose D | Yes | No | 0 | 1,373,496 | 0.00 | 0 |
30 Oct 23 | Growth Sponsor FEAC I B.V. Forbion | Warrant Class A Ordinary Shares | Sale back to company | Dispose D | Yes | No | 11.5 | 666,666 | 7.67 mm | 0 |
30 Oct 23 | Growth Sponsor FEAC I B.V. Forbion | Warrant Class A Ordinary Shares | Sale back to company | Dispose D | Yes | No | 11.5 | 731,619 | 8.41 mm | 0 |
27 Oct 23 | Growth Sponsor FEAC I B.V. Forbion | Class A Ordinary Shares | Conversion | Acquire C | Yes | No | 0 | 1,373,496 | 0.00 | 1,373,496 |
27 Oct 23 | Growth Sponsor FEAC I B.V. Forbion | Warrant Class A Ordinary Shares | Grant | Acquire A | Yes | No | 1.5 | 1,000,000 | 1.50 mm | 731,619 |
27 Oct 23 | Growth Sponsor FEAC I B.V. Forbion | Class B Ordinary Shares Class A Ordinary Shares | Conversion | Dispose C | Yes | No | 0 | 1,373,496 | 0.00 | 0 |
News
enGene To Present Details Of Its Pivotal Phase 1/2 LEGEND Study Of EG-70 In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ At The American Urology Association 2024 Annual Meeting
2 May 24
Guggenheim Initiates Coverage On enGene Holdings with Buy Rating, Announces Price Target of $34
15 Apr 24
UBS Initiates Coverage On enGene Holdings with Buy Rating, Announces Price Target of $37
28 Mar 24
enGene Holdings Q1 Net Loss Attributable To Common Shareholders $(10.7)M Or $(0.46) Per Share
11 Mar 24
Morgan Stanley Initiates Coverage On enGene Holdings with Overweight Rating, Announces Price Target of $40
8 Mar 24
Press releases
enGene Announces Hiring of Dr. Raj Pruthi as Senior Vice President, Urologic Oncology and Clinical Development
9 Apr 24
enGene Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development
9 Apr 24
engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development
9 Apr 24
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress
11 Mar 24
enGene To Present at the Leerink Partners Global Biopharma Conference
5 Mar 24